David Reardon

47PUBLICATIONS
454CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyGene expression (incl. microarray and other genome-wide approaches)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (47)

|Oct 06, 2026
Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial.

|Aug 05, 2026
Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma.

|Jul 29, 2026
Glioblastoma: Overcoming fundamental biological and delivery barriers to therapy.

|Jul 22, 2026
Single-nucleus multimodal spatial transcriptomics reveals spatial colocalization of neoantigen-expressing tumor cells and cognate T cells.

|Jul 15, 2026
Erdafitinib in Patients With Advanced Solid Tumors With FGFR Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts.

|Jun 03, 2026
Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Pageof 8

Frequent Collaborators

17 joint publications

Patrick Y Wen

13 joint publications

E Antonio Chiocca

13 joint publications

Keith Ligon

8 joint publications

Raymond Y Huang